Generation of CRISPR knockout of IDH1 in pancreatic ductal adenocarcinoma cell line: An optimal model to study pancreatic cancer metabolic reprogramming

Authors

Katerina Dukleska, MD, Thomas Jefferson UniversityFollow
Mahsa Zarei, PhD, Thomas Jefferson UniversityFollow
Ali Vaziri-Gohar, PhD, Thomas Jefferson UniversityFollow
Charles J. Yeo, MD, Thomas Jefferson UniversityFollow
Jonathan Brody, MD, Thomas Jefferson UniversityFollow
Jordan M. Winter, MD, Thomas Jefferson UniversityFollow

Files

Description

Introduction

• Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer-related death in the US.

• PDA is resistant to conventional chemotherapy; however, mechanisms that contribute to this chemoresistance are not well-described.

• The tumor microenvironment in PDA has a dense stromal reaction, which is thought to result in low oxygen and low nutrient conditions (Feig, C., et al. 2012).

• Isocitrate Dehydrogenase 1 (IDH1) has been identified as an enzyme that plays an important role in chemoresistance in PDA (Zarei, M., et al. In progress).

• We sought to establish an IDH1 knockout cell line to further study its role in PDA using the CRISPR-Cas9 targeted genome editing system.

Publication Date

4-25-2017

Keywords

Generation of CRISPR knockout of IDH1 in pancreatic ductal adenocarcinoma cell line: An optimal model to study pancreatic cancer metabolic reprogramming, Department of Surgery, Thomas Jefferson University

Disciplines

Medicine and Health Sciences | Surgery

Recommended Citation

Dukleska, MD, Katerina; Zarei, PhD, Mahsa; Vaziri-Gohar, PhD, Ali; Yeo, MD, Charles J.; Brody, MD, Jonathan; and Winter, MD, Jordan M., "Generation of CRISPR knockout of IDH1 in pancreatic ductal adenocarcinoma cell line: An optimal model to study pancreatic cancer metabolic reprogramming" (2017). Department of Surgery Posters. 8.
https://jdc.jefferson.edu/surgeryposters/8